Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug (NSAID)
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis (DISSCO Trial)
Phase 3
Waitlist Available
Led By Jean-Pierre Pelletier, MD, FRCPC
Research Sponsored by TRB Chemedica International SA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 728 days
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Pivotal Trial
Summary
This trial compares Diacerein and Celecoxib in patients aged 50 and older with knee osteoarthritis. Diacerein helps protect cartilage by blocking harmful substances, while Celecoxib reduces pain and inflammation. The study aims to determine which medication is more effective at reducing symptoms and preventing structural damage. Diacerein has been studied for its efficacy in reducing pain in knee osteoarthritis patients, with a focus on its cartilage-protective properties.
Eligible Conditions
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and 728 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 728 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change Form Baseline in WOMAC A Pain Subscale
Secondary study objectives
Absolute Changes From Baseline in Pain Visual Analogue Scale
Assessment of Joint Swelling, Effusion or Both
Change From Baseline in Patient's Global Assessment of Disease Activity
+5 moreOther study objectives
Cartilage Volume Loss From Baseline in the Lateral Compartment Using MRI
Cartilage Volume Loss From Baseline in the Medial Compartment Using MRI
Change From Baseline in Global Stiffness Using WOMAC Subscale
+3 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: DiacereinExperimental Treatment2 Interventions
One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
Group II: CelecoxibActive Control2 Interventions
One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
Diacerein
FDA approved
Find a Location
Who is running the clinical trial?
TRB Chemedica International SALead Sponsor
2 Previous Clinical Trials
160 Total Patients Enrolled
ArthroLab Inc.Industry Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Osteoarthritis
50 Patients Enrolled for Osteoarthritis
Jean-Pierre Pelletier, MD, FRCPCPrincipal InvestigatorArthroLab Inc.
Jean-Pierre Raynauld, MD, FRCPCPrincipal InvestigatorOsteoarthritis Research Unit, University of Montreal Hospital Center